LA COMBINAISON INHIBITEURS ABCG2-SACITUZUMAB GOVITECAN (IMMU-132) SURMONTE LA RESISTANCE A SN-38 DANS LES CANCERS EXPRIMANT TROP-2

• 收藏
• 分享

专利权人:

IMMUNOMEDICS; INC.

发明人:

CHANG, CHIEN-HSING,GOLDENBERG, DAVID M.

申请号：

CA3011372

公开号：

CA3011372A1

申请日:

2017.02.10

申请国别(地区):

CA

年份:

2017

代理人:

摘要：

The present invention relates to therapeutic ADCs comprising a drug attached to an anti-cancer antibody or antigen-binding antibody fragment. Preferably the drug is SN-38. More preferably the antibody or fragment thereof binds to Trop-2 and the therapy is used to treat a Trop-2 positive cancer. Most preferably the antibody is hRS7. The ADC is administered to a subject with a cancer in combination with an ABCG2 inhibitor. The combination therapy is effective to treat cancers that are resistant to drug alone and/or to ADC alone.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/